Navigation Links
Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
Date:1/26/2009

SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that Vincent P. Mihalik has been appointed Senior Vice President, Sales and Marketing and Chief Commercial Officer. Mr. Mihalik brings more than 30 years of experience across multiple commercial roles, including global product development, sales and sales management, product launches and brand management. His career has focused on diabetes, with numerous leadership roles at leading pharmaceutical companies.

Before joining Amylin, Mr. Mihalik was Vice President of Global Brand Development Diabetes and Endocrine Platform Team Leader at Eli Lilly and Company, where he managed the second largest therapeutic area for the company and was responsible for product development beyond Phase 2b to launch for lifecycle planning and commercialization. Previously, Mr. Mihalik was Business Unit Head of Diabetes Care for Lilly U.S., where he was responsible for the launch, sales and marketing for Actos(R) (pioglitazone), insulin injection pens (Humulin(R), Humalog(R)) and the preparation for the launch of Cialis(R) (tadalafil) in the U.S.

Mr. Mihalik has extensive previous experience in diabetes and has a successful track record in leadership at a number of companies focused on improving care for patients. These include: Roche Diagnostics Corporation (Senior Vice President and General Manager for Lab Systems and Molecular Biochemicals), Boehringer Mannheim Group (Executive Vice President of Human Resources for BM Global and President Diabetes Care North America) and Baxter Healthcare (President Scientific Products Biomedical and General Manager, Pandex Diagnostic Research and Development Center).

"Vince brings extensive sales and marketing expertise in the area of diabetes, and has a proven track record for incr
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
2. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
3. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
4. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals to Webcast Third Quarter Results
7. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
8. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
9. Amylin and Lilly Set Date and Time for Conference Call
10. Amylin Pharmaceuticals to Webcast Second Quarter Results
11. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... The market for ... and is forecasted to reach $4B in 2015. , ... San Francisco, CA (PRWEB) June 28, 2010 -- In spite of ... digital brain health and fitness tools, grew 35% in 2009. “The convergence of ...
... Fla. , June 26 Orexigen® Therapeutics, Inc. (Nasdaq: ... demonstrating that treatment with Contrave® resulted in significant improvements in depressive ... eating in overweight and obese patients with major depression.   , ... The primary endpoint ...
... , June 25 Interleukin Genetics, Inc. (NYSE ... 24, 2010 , it received notification from the Corporate Compliance ... Exchange intends to initiate proceedings to delist the Company,s common ... of the Exchange,s Company Guide due to stockholders, equity of ...
Cached Biology Technology:New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 2New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 3New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 4New Report Finds A Brain Health Revolution in the Making, Driven by Digital Technology and Neuroplasticity Research 5Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 2Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 3Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 4Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 5Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex 2
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... between chronic cerebrospinal venous insufficiency (a reported condition ... drain blood from the brain and spinal cord ... sclerosis indicate that a minimally invasive endovascular treatment ... short-term improvement in physical- and mental health-related quality ...
... Cell therapy may present an option for patients with ischemic ... repair the damaged areas of their hearts, and may pave ... trial, which will be presented as a late-breaking clinical trial ... (ACC) scientific session. This is the largest study to ...
... New Rochelle, NY, March 21, 2012Healthy individuals who carry ... autism have structural differences in their brains that may ... increases vulnerability for autism. The results of this innovative ... the groundbreaking neuroscience journal Brain Connectivity, a ...
Cached Biology News:Interventional radiologists see 'significant' symptom relief in MS patients 2Interventional radiologists see 'significant' symptom relief in MS patients 3Cell therapy using patient's own bone marrow may present option for heart disease 2Cell therapy using patient's own bone marrow may present option for heart disease 3
... EPS 3501 XL Power Supply, 1. 3500 ... constant current, constant power, and linear voltage ... to focused equilibrium in IPG strips quickly ... compensate for variations in gel thickness, sample ...
...
Request Info...
... ESGRO Complete Derivation Kit is intended ... cells from delayed blastocysts in serum-free ... Clonal Grade ... Blastocyst Incubation Medium Trypsin Solution ...
Biology Products: